Steven M. Hyman

<table class="infobox infobox-researcher">
<tr>
<th class="infobox-header" colspan="2">Steven M. Hyman</th>
</tr>
<tr>
<td class="infobox-image" colspan="2">
<em>Photo placeholder</em>
</td>
</tr>
<tr>
<td class="label">Affiliations</td>
<td>Harvard University<br>Broad Institute</td>
</tr>
<tr>
<td class="label">Country</td>
<td>USA</td>
</tr>
<tr>
<td class="label">H-index</td>
<td>200</td>
</tr>
<tr>
<td class="label">ORCID</td>
<td><a href="https://orcid.org/0000-0003-2605-0010" target="_blank">0000-0003-2605-0010</a></td>
</tr>
<tr>
<td class="label">Research Focus</td>
<td>[Alzheimer's Disease](/diseases/alzheimers), Psychiatric disorders</td>
</tr>
<tr>
<td class="label">Mechanisms</td>
<td>[Genetics](/mechanisms/familial-alzheimers-genetics), Drug development</td>
</tr>
</table>

Steven M. Hyman

Overview

Steven M. Hyman is a leading researcher in the field of neurodegenerative diseases, affiliated with Harvard University and Broad Institute. Their research focuses on Genetics, Drug development, with particular emphasis on Alzheimer's Disease and Psychiatric disorders. With an h-index of 200, Hyman is among the most cited researchers in the neuroscience field[@orcid2026].

<table class="infobox infobox-researcher">
<tr>
<th class="infobox-header" colspan="2">Steven M. Hyman</th>
</tr>
<tr>
<td class="infobox-image" colspan="2">
<em>Photo placeholder</em>
</td>
</tr>
<tr>
<td class="label">Affiliations</td>
<td>Harvard University<br>Broad Institute</td>
</tr>
<tr>
<td class="label">Country</td>
<td>USA</td>
</tr>
<tr>
<td class="label">H-index</td>
<td>200</td>
</tr>
<tr>
<td class="label">ORCID</td>
<td><a href="https://orcid.org/0000-0003-2605-0010" target="_blank">0000-0003-2605-0010</a></td>
</tr>
<tr>
<td class="label">Research Focus</td>
<td>[Alzheimer's Disease](/diseases/alzheimers), Psychiatric disorders</td>
</tr>
<tr>
<td class="label">Mechanisms</td>
<td>[Genetics](/mechanisms/familial-alzheimers-genetics), Drug development</td>
</tr>
</table>

Steven M. Hyman

Overview

Steven M. Hyman is a leading researcher in the field of neurodegenerative diseases, affiliated with Harvard University and Broad Institute. Their research focuses on Genetics, Drug development, with particular emphasis on Alzheimer's Disease and Psychiatric disorders. With an h-index of 200, Hyman is among the most cited researchers in the neuroscience field[@orcid2026].

Hyman's work spans multiple aspects of neurodegeneration, contributing to our understanding of the molecular mechanisms that underlie diseases such as Alzheimer's Disease and Psychiatric disorders. Their research group has made significant contributions to the fields of Genetics, Drug development, publishing in high-impact journals including leading neuroscience journals.

Based at Harvard University and Broad Institute, Hyman collaborates with researchers across multiple institutions worldwide, working to advance therapeutic strategies for neurodegenerative conditions.

Research Focus

Disease Areas

• [Alzheimer's Disease](/diseases/alzheimers-disease)
• Psychiatric disorders

Mechanisms of Interest

• [Genetics](/mechanisms/familial-alzheimers-genetics)
• Drug development

Programmatic Emphasis

The work frequently sits at the interface of discovery science and implementation, using study designs that can be transferred from observational cohorts to interventional studies. This makes the profile especially relevant for NeuroWiki pages that connect molecular mechanisms to treatment strategy, trial design, and patient stratification.

Methods and Data Strategy

The program also supports comparative interpretation across related disorders, helping distinguish disease-general stress biology from disease-specific pathomechanisms. That distinction is important for mechanistic ranking and for selecting therapeutic targets with realistic translational potential.

Translational Relevance

This orientation improves actionability of mechanistic knowledge graphs because it links entities and pathways to measurable clinical decisions. Pages connected to this profile should therefore prioritize explicit mechanism-to-outcome chains, with clear assumptions and evidence quality labels.

Key Publications

Recent Research

Recent PubMed-indexed publications (2025-present):

Collaborators and Research Network

[John Hardy](/researchers/john-hardy), [Lennart Mucke](/researchers/lennart-mucke)

Institutional Context

Open Questions and Future Directions

• How can Genetics, Drug development signals be standardized across cohorts and sites without losing disease-stage sensitivity?
• Which biomarker combinations best separate causal mechanism activity from downstream epiphenomena?
• What trial designs can most efficiently translate mechanistic findings in Alzheimer's Disease and Psychiatric disorders into clinically meaningful interventions?

External Links

• ORCID: [https://orcid.org/0000-0003-2605-0010](https://orcid.org/0000-0003-2605-0010)
• Google Scholar: [Search for Steven M. Hyman](https://scholar.google.com/scholar?q=author%3A%22Steven+M.+Hyman%22)
• PubMed: [Author search for Steven M. Hyman](https://pubmed.ncbi.nlm.nih.gov/?term=Steven+M.+Hyman%5BAuthor%5D)

See Also

• [Researchers and Institutions Index](/researchers)
• [Diseases Index](/diseases)
• [Mechanisms Index](/mechanisms)

References